Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women
- 1 April 2006
- journal article
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 194 (4) , 1034-1041
- https://doi.org/10.1016/j.ajog.2005.10.192
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studiesBMJ, 2005
- Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsiaThe Journal of Maternal-Fetal & Neonatal Medicine, 2005
- Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsiaAmerican Journal of Obstetrics and Gynecology, 2004
- Circulating Angiogenic Factors and the Risk of PreeclampsiaNew England Journal of Medicine, 2004
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsiaJournal of Clinical Investigation, 2003
- Predictors of pre-eclampsia in women at high riskAmerican Journal of Obstetrics and Gynecology, 1998
- Risk factors associated with preeclampsia in healthy nulliparous womenPublished by Elsevier ,1997
- Risk factors for preeclampsia in healthy nulliparous women: A prospective multicenter studyAmerican Journal of Obstetrics and Gynecology, 1995
- Preeclampsia: An endothelial cell disorderAmerican Journal of Obstetrics and Gynecology, 1989